Cellyan Biotechnology Co., Ltd HKPD
2.00 USD +0.06 (+3.09%)
Nov 4, 2026, 9:51 AM EST
1.99 Day range 2.05
1.62 52-week range 29.00
- YTD
- -87.86%
- 1 year
- -91.67%
Financial health
Altman Z-Score
2.46 Grey zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 3
Valuation
P/E -11.7×
FY 2023 5y median 2.0× FY 2026
P/S 1.0×
FY 2023 5y median 1.1× FY 2026
P/B 1.4×
FY 2023 5y median 3.4× FY 2026
P/FCF -17.0×
FY 2023 5y median 1.2× FY 2026
EV/EBITDA -45.3×
FY 2023 5y median 9.1× FY 2026
EV/Sales 1.1×
FY 2023 5y median 1.2× FY 2026
FCF Yield -5.9%
FY 2023 5y median 1.0% FY 2026
Profitability
Gross Margin 10.3%
FY 2023 5y median 16.6% FY 2026
Operating Margin -7.4%
FY 2023 5y median 4.5% FY 2026
Net Margin -8.5%
FY 2023 5y median 3.9% FY 2026
ROE -11.9%
FY 2023 5y median 15.4% FY 2026
ROIC -9.2%
FY 2023 5y median 10.4% FY 2026
ROA -8.8%
FY 2023 5y median 7.5% FY 2026
Growth (YoY)
Revenue -33.9%
FY 2023 FY 2026
Operating Income -853.5%
FY 2023 FY 2026
EPS (diluted) -1516.7%
FY 2023 FY 2026
Free Cash Flow -290.0%
FY 2023 FY 2026
Financial Health
Current Ratio 3.9×
FY 2023 5y median 2.7× FY 2026
Quick Ratio 3.7×
FY 2023 5y median 2.5× FY 2026
Debt / Equity 0.1×
FY 2023 5y median 0.5× FY 2026
Net Debt / EBITDA -3.3×
FY 2023 5y median 0.3× FY 2026
Interest Coverage -7.5×
FY 2023 5y median 10.4× FY 2026
Dividends
Dividend Yield 0.0%
FY 2023 5y median 0.0% FY 2026
Payout Ratio 0.0%
FY 2023 5y median 0.0% FY 2026
Annual · latest fiscal year ends 2026-03-31